ConvaTec Group PLC Non-Executive Director appointment (7984S)
13 Luglio 2020 - 12:00PM
UK Regulatory
TIDMCTEC
RNS Number : 7984S
ConvaTec Group PLC
13 July 2020
Non-Executive Director appointment
Reading, United Kingdom (13 July 2020)
ConvaTec Group Plc ("ConvaTec" or "the Company") announces the
appointment of Professor Constantin Coussios FREng as a
Non-Executive Director of the Company with effect from 1 September
2020.
Constantin is an internationally recognised key opinion leader
in the fields of biomedical engineering, image-guided therapy and
drug delivery, and the recipient of the 2017 Silver Medal by the
UK's Royal Academy of Engineering. He is currently the Director of
the Institute of Biomedical Engineering, University of Oxford,
which is focused on the disciplines of non-invasive therapies, drug
delivery, regenerative medicine, medical imaging, AI in healthcare,
neurotechnology and biomaterials. In addition to his role as
Director, he also has a proven track record of translating research
into technology through academic entrepreneurship. He has served as
founder, CEO and CTO of three successful spin-outs, including
OrganOx whose normothermic organ preservation technology is in all
UK transplant centres, and many European and North-American
centres. Between 2014 and 2020, he directed and led the Oxford
Centre for Drug Delivery Devices, a cross-disciplinary centre
investigating the combination of medical devices and nanotechnology
to improve the delivery and efficacy of therapeutics in oncology in
collaboration with ten pharmaceutical and medical device
companies.
John McAdam, Chairman of ConvaTec, commented:
"I am delighted to welcome Constantin to our Board. He is an
eminent academic in the field of biomedical engineering and brings
first-hand experience of developing innovative products from
concept through development, regulatory approval to
commercialisation. His extensive experience and insight shall be
invaluable as we focus on innovation to help drive our
transformation."
Constantin is a Statutory Professor of Biomedical Engineering,
University of Oxford, and Professorial Fellow of Magdalen College.
He is also a non-executive director of OrganOx Limited, OxSonics
Limited and OrthoSon Limited; and a Trustee of the Oxford
Transplant Foundation.
No other information requires disclosure in accordance with
Listing Rule 9.6.13.
This announcement is made in accordance with Listing Rule
9.6.11R(1).
Enquiries:
Analysts and Investors
Mark Reynolds, Director Investor Relations +44 (0)7551 036
625
ir@convatec.com
Media
Buchanan: Charles Ryland/Chris Lane/Vicky Hayns +44 (0)207 466
5000
About ConvaTec
ConvaTec is a global medical products and technologies company
focused on therapies for the management of chronic conditions. The
Company is listed on the London Stock Exchange (stock symbol: CTEC)
and has established market positions in advanced wound care, ostomy
care, continence and critical care, and infusion care. ConvaTec's
products provide a range of clinical and economic benefits,
including infection prevention, protection of at-risk skin,
improved patient outcomes and reduced total cost of care.
www.convatecgroup.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
BOAKKNBNOBKKPOD
(END) Dow Jones Newswires
July 13, 2020 06:00 ET (10:00 GMT)
Grafico Azioni Convatec (LSE:CTEC)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Convatec (LSE:CTEC)
Storico
Da Apr 2023 a Apr 2024
